Large numbers of individuals who have been infected with SARS-CoV-2, the virus responsible for COVID-19, continue to experience a constellation of symptoms long past the time that they have recovered from the acute stages of their illness. Often referred to as “long COVID,” these symptoms, which can include fatigue, shortness of breath, palpitations, cognitive dysfunction (“brain fog”), sleep disorders, fevers, gastrointestinal symptoms, anxiety, depression, and others, can persist for months and can range from mild to incapacitating. Although still being defined, these effects can be collectively referred to as postacute sequelae of SARS-CoV-2 infection (PASC). 1 The magnitude of this problem is not yet known, but given the millions of individuals worldwide who have had, or will have, COVID-19, the societal impacts are likely to be profound and long lasting. 2-5 It is widely acknowledged that systematic study is needed to develop an evidence-based approach for caring for patients with PASC. At present, there is a dearth of rigorous scientific evidence regarding effective assessment and treatment of PASC that prevents the creation of evidence-based clinical guidelines. However, the US health system is currently seeing an increase in the number of patients presenting with PASC, and there is an urgent need for clinical guidance in treating these patients. The goal of this, and future statements, is to provide practical guidance to clinicians in the assessment and treatment of patients presenting with PASC.